Katarina Luptakova, MD

Katarina Luptakova is CMO, bringing more than a decade of hematology and oncology drug development experience across publicly-traded biotech and pharmaceutical companies. She has built a track record of successful global drug registrations, including Zejula (niraparib) for ovarian cancer, and development of Blenrep (belantamab mafodotin) for multiple myeloma.

Most recently, Dr. Luptakova served as Chief Medical Officer of Xilio Therapeutics, where she built the company’s clinical and medical organization and advanced multiple tumor-activated immunotherapies from IND through proof-of-concept studies, in addition to supporting a global license and collaboration agreement with Gilead Sciences. Previously, as Vice President of Clinical Development at Constellation Pharmaceuticals (acquired by MorphoSys), she led pelabresib development for myelofibrosis. She also held clinical leadership roles at TESARO (acquired by GSK) and in global medical affairs at Takeda Oncology supporting Ninlaro (ixazomib) launch.

She began her career as an attending physician in Hematologic Malignancies and Bone Marrow Transplant at Beth Israel Deaconess Medical Center, following clinical and research fellowship training at Beth Israel Deaconess Medical Center and Harvard Medical School. 

Dr. Luptakova earned her M.D., summa cum laude, from Comenius University School of Medicine in Bratislava, Slovakia.